April 25, 2018 / 12:03 PM / in 7 months

GSK rules out entering Shire takeover battle

The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

LONDON (Reuters) - GlaxoSmithKline’s (GSK.L) chief executive said on Wednesday she had no interest in acquiring Shire (SHP.L), the London-listed rare diseases specialist that Takeda Pharmaceutical (4502.T) hopes to buy for some $64 billion.

Emma Walmsley, speaking to reporters after first-quarter results, said the British drugmaker’s focus was on deals to acquire early-stage experimental drugs that would help rebuild the company’s pharmaceuticals pipeline.

Reporting by Ben Hirschler; editing by Jason Neely

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below